Memantine Reduces Premature Atrial Contractions and New-Onset Atrial Fibrillation

Targeting the Cardiac Glutamatergic System in Atrial Ectopy

Premature atrial contractions are frequently encountered in clinical practice and serve as independent predictors for the development of atrial fibrillation, stroke, and heart failure [1, 2]. Despite their clinical significance, pharmacological options for suppressing these ectopies remain limited, often relying on medications with narrow therapeutic windows or significant side-effect profiles [3, 4]. Traditional antiarrhythmic strategies primarily target ion channels, yet the risk of proarrhythmia and prolongation of the corrected QT interval (the time required for the ventricles to depolarize and repolarize) remains a constant concern for clinicians managing complex patients [5, 6]. Emerging evidence suggests that the heart possesses a functional cardiac glutamatergic system (a signaling network using glutamate to modulate cellular activity), where N-methyl-D-aspartate receptors (proteins that typically act as glutamate-gated ion channels in the nervous system) play a role in regulating atrial electrophysiology [1, 7]. A new study now offers fresh insights into the efficacy and safety of targeting this pathway to manage atrial ectopy.

Trial Design and Patient Characteristics

The researchers conducted an investigator-initiated, phase 2, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of memantine in suppressing atrial ectopy. The study population consisted of symptomatic adults who presented with frequent premature atrial contractions, which the protocol defined as a count of at least 1000 per 24 hours. This threshold ensured that the enrolled patients had a high enough burden of ectopy to measure meaningful clinical changes. Participants were randomly assigned to receive either memantine or a placebo for a treatment duration of 6 weeks, allowing for an assessment of both short-term efficacy and early safety signals. The primary end point of the study was the percentage change in the mean 24-hour premature atrial contraction count from the baseline measurement to the end of the 6-week treatment period. To maintain the statistical integrity of the results and account for any participants who may have discontinued the medication, the researchers performed the primary analysis in the intention-to-treat population (a statistical method where all participants are analyzed in their originally assigned groups, regardless of whether they completed the full course of treatment). This approach provides a more realistic estimate of how the drug might perform in a real-world clinical setting where patient adherence may vary. Beyond the primary outcome, the trial tracked several prespecified secondary end points to provide a comprehensive view of the drug's antiarrhythmic potential. These included the responder rate, which the authors defined as a reduction in premature atrial contractions of 50% or greater. Additionally, the study measured the percentage change in the burden of nonsustained atrial tachycardia (short bursts of rapid atrial rhythms that do not meet the full criteria for sustained tachycardia) and the cumulative incidence of new-onset atrial fibrillation. By including these metrics, the trial sought to determine if reducing simple ectopy could translate into a lower risk of more complex and clinically dangerous tachyarrhythmias.

Significant Reductions in Atrial Ectopy and Tachyarrhythmia

The efficacy analysis included 241 patients who completed the treatment protocol, providing sufficient statistical power to evaluate the impact of N-methyl-D-aspartate receptor antagonism on atrial rhythm. The researchers found that memantine resulted in a significantly greater reduction in the mean 24-hour premature atrial contraction count compared to the placebo group. Specifically, the between-group difference was 47.1 percentage points (P=0.0045), indicating a substantial suppression of atrial ectopy. This primary outcome was mirrored by the responder rate, which the study defined as the proportion of patients achieving at least a 50% reduction in their baseline ectopy burden. In the memantine group, the responder rate reached 52.4%, whereas only 23.1% of the placebo group met this clinical threshold (P<0.0001). Beyond the reduction of isolated premature beats, the medication demonstrated a measurable effect on more complex atrial arrhythmias. Memantine reduced the burden of nonsustained atrial tachycardia, which refers to short, self-terminating bursts of rapid atrial activity, with a between-group difference of 30.98 percentage points (P=0.0043). Perhaps most clinically significant for long-term stroke and heart failure prevention was the impact on the development of sustained rhythm disturbances. The cumulative incidence of new-onset atrial fibrillation was 4.8% in the memantine group compared to 23.9% in the placebo group (P<0.0001). These results suggest that targeting the cardiac glutamatergic system may not only suppress symptomatic ectopy but also potentially alter the progression toward more stable and dangerous atrial tachyarrhythmias, addressing a critical need in rhythm management.

Safety Profile and Clinical Implications

The safety data from this phase 2 trial indicate that memantine was well tolerated by the study population, with no drug-related serious adverse events reported during the 6-week treatment period. Clinicians managing patients with frequent ectopy often face concerns regarding the proarrhythmic potential or negative inotropic effects (the weakening of the heart's muscular contraction) of traditional antiarrhythmic agents; however, this study found no clinically meaningful differences in electrocardiographic (ECG) intervals or left ventricular function between the treatment and placebo groups. This stability in cardiac conduction and contractile performance suggests that memantine may offer a favorable safety profile for patients with symptomatic premature atrial contractions, particularly those for whom standard ion channel blockers might be contraindicated or poorly tolerated. These findings serve as a critical proof of concept for a non-ion channel-based therapeutic strategy that targets the cardiac glutamatergic system. While traditional therapies focus on sodium, potassium, or calcium channels, experimental studies have identified a functional cardiac glutamatergic system where N-methyl-D-aspartate receptors regulate atrial electrophysiology. Preclinical studies previously demonstrated that pharmacological antagonism of these N-methyl-D-aspartate receptors with memantine suppresses atrial arrhythmias, and this trial translates those findings into a clinical setting. By successfully modulating this pathway, the researchers have identified a potential method to address a significant therapeutic gap. The clinical relevance of these results is underscored by the fact that no pharmacological therapy is currently approved for the suppression of premature atrial contractions, despite their known risks. Premature atrial contractions are not merely benign findings; they are independently associated with atrial fibrillation, stroke, and heart failure. By reducing the burden of atrial ectopy and lowering the cumulative incidence of new-onset atrial fibrillation (4.8% versus 23.9%; P<0.0001), memantine may provide a pathway to mitigate the long-term sequelae associated with these rhythm disturbances. This study establishes a foundation for further investigation into the cardiac glutamatergic system as a viable target for rhythm management in patients at high risk for progressive atrial tachyarrhythmias.

References

1. Shen Y, Zeng C, Sun Y, et al. Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.. Circulation. 2026. doi:10.1161/CIRCULATIONAHA.125.079023

2. Park SM, Lee SY, Jung M, et al. Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure. Korean Circulation Journal. 2023. doi:10.4070/kcj.2023.0114

3. Shepherd J, Jones JJ, Frampton GK, Tanajewski Ł, Turner D, Price A. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. Health Technology Assessment. 2008. doi:10.3310/hta12280

4. Wang Z, Bian W, Yan Y, Zhang D. Functional Regulation of KATP Channels and Mutant Insight Into Clinical Therapeutic Strategies in Cardiovascular Diseases. Frontiers in Pharmacology. 2022. doi:10.3389/fphar.2022.868401

5. Kitaya S, Nakano M, Katori Y, Yasuda S, Kanamori H. QTc Interval Prolongation as an Adverse Event of Azole Antifungal Drugs: Case Report and Literature Review. Microorganisms. 2024. doi:10.3390/microorganisms12081619

6. Vu TD, Valentine J. Bigeminy with Prolonged QT Interval as an Ominous Sign for Impending Torsades de Pointes: A Case Report. Clinical Practice and Cases in Emergency Medicine. 2024. doi:10.5811/cpcem.19484

7. Malik BH, Hamid P, Khan S, Gupta D, Islam M. Correlation Between Donepezil and QTc Prolongation and Torsades de Pointes: A Very Rare Phenomenon. Cureus. 2019. doi:10.7759/cureus.6451